Metabolic effects of Lactobacillus reuteriDSM 17938 in people with type 2 diabetes: A randomized controlled trial

Diabetes, Obesity and Metabolism - Tập 19 Số 4 - Trang 579-589 - 2017
Reza Mobini1, Valentina Tremaroli1, Marcus Ståhlman1, Fredrik Karlsson2, Max Levin1, Maria Ljungberg3, Maja Sohlin3, Heléne Bertéus Forslund4, Rosie Perkins1, Fredrik Bäckhed5,1, Per‐Anders Jansson1
1Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
2Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
3Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
4Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
5Novo Nordisk Foundation Centre for Basic Metabolic Research, Section for Metabolic Receptology and Enteroendocrinology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Tóm tắt

AimsTo investigate the metabolic effects of 12‐week oral supplementation with Lactobacillus reuteri DSM 17938 in patients with type 2 diabetes on insulin therapy.Materials and methodsIn a double‐blind trial, we randomized 46 people with type 2 diabetes to placebo or a low (108 CFU/d) or high dose (1010 CFU/d) of L. reuteri DSM 17938 for 12 weeks. The primary endpoint was the effect of supplementation on glycated haemoglobin (HbA1c). Secondary endpoints were insulin sensitivity (assessed by glucose clamp), liver fat content, body composition, body fat distribution, faecal microbiota composition and serum bile acids.ResultsSupplementation with L. reuteri DSM 17938 for 12 weeks did not affect HbA1c, liver steatosis, adiposity or microbiota composition. Participants who received the highest dose of L. reuteri exhibited increases in insulin sensitivity index (ISI) and serum levels of the secondary bile acid deoxycholic acid (DCA) compared with baseline, but these differences were not significant in the between‐group analyses. Post hoc analysis showed that participants who responded with increased ISI after L. reuteri supplementation had higher microbial diversity at baseline, and increased serum levels of DCA after supplementation. In addition, increases in DCA levels correlated with improvement in insulin sensitivity in the probiotic recipients.ConclusionsIntake of L. reuteri DSM 17938 for 12 weeks did not affect HbA1c in people with type 2 diabetes on insulin therapy; however, L. reuteri improved insulin sensitivity in a subset of participants and we propose that high diversity of the gut microbiota at baseline may be important.

Từ khóa


Tài liệu tham khảo

Kumar V, 2015, Robbins and Cotran Pathologic Basis of Disease

10.2337/dc12-0413

10.1517/14656566.2014.944160

10.1038/nrgastro.2014.66

10.1371/journal.pone.0034938

10.3945/an.115.010587

10.1097/MD.0000000000004088

10.1016/j.diabres.2016.06.014

10.1002/mnfr.201600240

10.1038/nature12198

10.1038/nature08821

10.1194/jlr.R500013-JLR200

10.1371/journal.pone.0043910

10.1093/ajcn/51.6.1106

10.1038/sj.ejcn.1600732

10.1088/0957-0233/20/10/104035

10.1152/ajpendo.1979.237.3.E214

10.1053/j.gastro.2008.03.021

10.1016/j.nut.2011.08.013

Mohamadshahi M, 2014, Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: a randomized controlled clinical trial, J Res Med Sci, 19, 531

Ostadrahimi A, 2015, Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double‐blind placebo‐controlled clinical trial, Iran J Public Health, 44, 228

10.1016/j.clnu.2015.11.011

10.1530/EJE-14-0554

10.2337/dc14-2690

10.1017/S0007114510002874

10.1038/ijo.2011.153

10.1038/nutd.2013.28

10.1038/nrmicro2209-c2

10.1038/nature07540

10.1038/nature12506

10.1038/nature16504

10.1074/jbc.M111.305789

10.2337/db13-0639

10.2337/db11-0030

10.1007/s11892-011-0187-x

10.1016/j.cmet.2009.08.001

10.1111/j.1348-0421.2004.tb03526.x

10.1038/nature15766

Thông tin
Thông tin xuất bản

Diabetes, Obesity and Metabolism

Tập 19 Số 4

579-589

Thông tin tác giả